

REMARKS

Pursuant to 37 CFR § 1.126, Applicants request that the Examiner renumber Claim 18, as Claim 36. Applicants' apologize for the inadvertent numbering of the new claims. For convenience in this response, Applicants have renumbered Claim 18 to Claim 36 in the presently amended claims. Pursuant to the restriction requirement election, however, please note that the claims of Group I, which include Claim 36, are cancelled as non-elected subject matter.

As previously stated, Applicants elected the claims of Group II (Claims 22-24 and 27). Applicants request that Claim 28, 31 and 32 be included in Group II, since these claims depend from Claim 27 – part of Group II – or depend from a claim dependent from Claim 27. Applicants amended Claim 28 to include the structure of the compound of Formula I. Claim 32 was amended to further define the antigen.

Applicants also added new claim 44. No new matter was added by this amendment. Support for the amendment may be found in the cancelled claims of Group IV.

Claims 19-21, 25-26, 29-30 and 33-41 were cancelled as non-elected subject matter. Applicants reserve the right to file divisional applications to any subject matter cancelled herein.

Applicants also request that the claims of Group IV (method of treatment claims Claims 42-43, presently withdrawn) be rejoined upon a finding of patentability of the claims presently before the Examiner.

CONCLUSION

It is submitted that the Applicant has fully complied with the Examiner's restriction requirement. Early examination and allowance of the claims is respectfully requested.

Respectfully submitted,

Date: January 11, 2008  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4288

/ Martha G. Munchhof /  
Martha G. Munchhof  
Attorney for Applicant(s)  
Reg. No. 47,811